Cube Dx GmbH is a leading provider of molecular microbiology and viral diagnostics solutions. Their innovative technology, called hyborg, allows for the rapid and targeted detection of over 100 microbial species and resistance genes directly from whole blood samples, all within just 3 hours. One of Cube Dx's key focus areas is the diagnosis and treatment of sepsis, a life-threatening condition caused by a dysregulated immune response to an infection.

Sepsis affects millions of people worldwide, with a high mortality rate and significant socioeconomic burden. Cube Dx's hyborg system enables healthcare professionals to quickly identify the causative pathogen of sepsis, helping to guide the appropriate antimicrobial therapy and minimize the development of antibiotic resistance. Traditionally, detection methods for sepsis rely on culturing microorganisms from blood samples, which can be time-consuming, taking up to 48 hours for results.

Cube Dx's technology offers a faster and more efficient alternative, allowing for timely interventions and improved patient outcomes. With their cutting-edge solutions, Cube Dx is revolutionizing the field of infectious disease diagnostics, helping healthcare professionals fight against infections and diagnose early, ultimately saving lives